Every 8-K that Acumen Pharmaceuticals, Inc. (ABOS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ABOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABOS filings page.
Acumen Pharmaceuticals, Inc. reported second quarter 2026 results and updated progress on its Alzheimer’s disease pipeline. For the quarter ended June 30, 2026, the company recorded a net loss of $32.7 million, improved from $41.0 million a year earlier, as research and development expenses declined to $27.8 million from $37.1 million, mainly from lower manufacturing, materials and CRO costs tied to the ALTITUDE-AD trial. General and administrative expenses were stable at $4.7 million.
Cash, cash equivalents and marketable securities totaled $110.2 million as of June 30, 2026, down from $128.4 million at March 31, 2026, and are expected to fund current clinical and operational activities into early 2027. The balance sheet showed total assets of $116.0 million, total liabilities of $58.7 million and stockholders’ equity of $57.3 million, with short-term debt of $19.7 million and long-term debt of $11.9 million. The company raised $35.4 million net from a private placement in the first half of 2026.
Operationally, Acumen highlighted its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in 542 participants with early Alzheimer’s disease, with topline results expected in late 2026, and continued development of its Enhanced Brain Delivery™ (EBD™) program, targeting an IND filing for a lead EBD candidate in mid-2027.
Acumen Pharmaceuticals has nominated two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for Alzheimer’s disease under its collaboration with JCR Pharmaceuticals and has exercised its option to license and develop them. The candidates combine Acumen’s amyloid-beta oligomer–selective antibodies with JCR’s J-Brain Cargo blood-brain barrier–penetrating technology.
Both candidates showed strongly enhanced brain penetration in non-human primates, with antibody levels 14–40x higher than native antibodies at 24 hours, low anemia risk and no observed adverse events across tested species. They also demonstrated favorable stability and plasma pharmacokinetics after subcutaneous dosing. Acumen is conducting Investigational New Drug–enabling activities to support a planned IND submission in mid-2027 while continuing its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in early Alzheimer’s disease.
Acumen Pharmaceuticals, Inc. reported results of its 2026 annual stockholder meeting. Stockholders elected three Class II directors to serve until the 2029 annual meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders also approved the Company’s Amended and Restated 2021 Equity Incentive Plan. Quorum was strong, with 57,051,456 of 72,227,580 shares outstanding, or approximately 78.99%, present or represented by proxy at the meeting.
Acumen Pharmaceuticals reported first quarter 2026 results and updated progress on its Alzheimer’s programs. Cash, cash equivalents and marketable securities were $128.4 million as of March 31, 2026, up from $116.9 million at December 31, 2025, helped by a March private placement that generated $35.75 million in gross proceeds. Management expects this cash to fund current clinical and operational activities into early 2027.
R&D expenses fell to $16.5 million from $25.3 million a year earlier as ALTITUDE-AD Phase 2 enrollment completed, while G&A declined to $4.7 million from $5.1 million. Net loss narrowed to $20.7 million from $28.8 million, or $0.33 per share. The company reiterated plans to report topline Phase 2 ALTITUDE-AD data for sabirnetug in late 2026 and to target an IND filing for a lead EBD enhanced brain-delivery candidate in mid-2027.
Acumen Pharmaceuticals reported a larger full-year 2025 net loss while funding late-stage Alzheimer’s programs. For the year ended December 31, 2025, the company recorded a net loss of $121.3 million, compared with $102.3 million in 2024, driven mainly by higher research and development spending.
R&D expenses rose to $104.9 million from $93.8 million, reflecting manufacturing, clinical and Enhanced Brain Delivery (EBD™) research costs, while G&A expenses declined slightly to $18.9 million. Cash, cash equivalents and marketable securities totaled $116.9 million as of December 31, 2025, which management expects to fund current clinical and operational activities into early 2027. A $35.75 million private placement in March 2026 further supports development.
The company’s lead antibody sabirnetug (ACU193) is being tested in the Phase 2 ALTITUDE-AD trial in early Alzheimer’s disease, with topline results expected in late 2026. Acumen is also advancing an EBD program that showed markedly higher brain exposure in non-human primates, with an IND filing for a lead clinical candidate targeted for mid-2027.
Acumen Pharmaceuticals is raising about $35.75 million through a private placement of 10,833,331 common shares at $3.30 per share with institutional investors. The deal is expected to close on March 16, 2026, subject to customary conditions. The company plans to use the proceeds primarily to advance its Enhanced Brain Delivery (EBD™) program, including preclinical work to select a lead clinical candidate, and for working capital and general corporate purposes. Acumen also granted investors registration rights to resell the new shares after the company files and clears a resale registration statement.
Acumen Pharmaceuticals, Inc. filed a current report to highlight that it has posted an updated corporate presentation on its investor website. The presentation now includes nonclinical murine brain exposure data supporting its Enhanced Brain Delivery (EBD™) program that was presented at the 2025 Clinical Trials on Alzheimer’s Disease conference, updated views of previously presented fluid biomarker data from its Phase 1 INTERCEPT-AD study, and the addition of ACU234 to the company’s pipeline in connection with the EBD program. The presentation is furnished as Exhibit 99.1 and, along with this disclosure, is designated as furnished rather than filed under securities law.
Acumen Pharmaceuticals filed a Form 8-K announcing it reported financial results and business highlights for the quarter ended September 30, 2025. The company furnished the details via an earnings press release attached as Exhibit 99.1.
Acumen also furnished an updated corporate presentation (Exhibit 99.2) and posted it on its investor website. The presentation was updated to reflect the company’s cash, cash equivalents and marketable securities balance as of September 30, 2025. The information in Items 2.02 and 7.01 was furnished rather than filed.
Acumen Pharmaceuticals (ABOS) appointed Dr. George Golumbeski to its Board and as Chairman, effective November 6, 2025. He will serve as a Class II director until the 2026 annual meeting and was deemed independent under Nasdaq rules, replacing Dr. Sean Stalfort as Chairman.
Under the company’s director compensation policy, he received an initial option for 50,000 shares at the closing price on the grant date, with a 10-year term vesting monthly over three years. He will receive a $40,000 annual Board retainer and a $30,000 annual Chairman retainer. The company entered into its standard director indemnification agreement with him, and disclosed no related-party arrangements.
Acumen Pharmaceuticals reported that it has furnished an earnings press release and posted an updated investor presentation that reflects the companys cash, cash equivalents and marketable securities balance as of June 30, 2025. The filing states these materials are furnished as Exhibits 99.1 and 99.2 and explicitly notes that the furnished information is not being "filed" under the Exchange Act and is not incorporated by reference in other securities filings.
The Form 8-K does not include numeric financial results within the filing itself; instead it directs readers to the furnished press release and presentation for details. The company also states that the submission is not an admission as to materiality of any Regulation FD disclosures.